Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
die Eigenproduktion entsprechend erhht
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
FDA as a Category 2 bulk substance (503A/503B compounding lists) Both BPC-157 and TB-500 included on the World Anti-Doping Agency (WADA) Prohibited List under Peptide Hormones, Growth Factors, Related Substances, and Mimetics Supplied strictly as a Research Use Only (RUO) material PPE required: nitrile gloves, lab coat, protective eyewear
Check out our extensive video library
US$ 21.29
US$ 25.69
US$ 25.66
US$ 28.21
.png)
US$ 21.86
US$ 28.73
US$ 25.60
US$ 23.96
US$ 21.90
US$ 24.34
US$ 21.08
